By Eric Topol
With unique contributions from forty five well known overseas professionals, this 3rd variation stands on my own because the such a lot complete, modern view of the biology, body structure, and administration of acute coronary syndromes (ACS)-offering 32 chapters that span the state-of-the technological know-how within the box and supply exciting discussions on CRP and different disorder markers, microcirculation, stem phone treatment, and the improvement of specialised facilities for ACS remedy.
Read Online or Download Acute Coronary Syndromes, Third Edition PDF
Similar immunology books
Within the particularly few many years because the creation of HIV into the human inhabitants, editions of the virus have diverged to such an volume that, have been the dialogue approximately anything except viruses, stated editions may simply be labeled as diverse species. This ebook will ponder those evolutionary adaptations, in addition to the various and, from time to time, opposing theories trying to clarify them.
Computer-based layout and modeling, computational methods, and instrumental equipment for elucidating molecular mechanisms of protein folding and ligand-acceptor interactions are incorporated in Volumes 202 and 203, as are genetic and chemical tools for the construction of sensible molecules together with antibodies and antigens, enzymes, receptors, nucleic acids and polysaccharides, and medication
- Viruses and nanotechnology
- New generation vaccines
- Systemic Vasculitides: Current Status and Perspectives
- Principles and Methods of Immunotoxicology, Volume 1
Extra info for Acute Coronary Syndromes, Third Edition
Bernini F. HMG-CoAreductase inhibitorsreduce MMP-9 secretion by nlacrophages. Arterioscler Thromb V a c Biol 1998; 18: 167 I - 1678. 1 SO. Cheng JW, Ngo MN. Currentperspective on the use of angiotensin-converting enzyme inhibitors i n the management of coronary (atherosclerotic) artery disease. Ann Pharmacother I 9 9 7 3 1 :1499- 1506. 151. HOPE Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramapril. on death from cardiovascular causes, myocardial infarction. stroke in high-risk patients.
Fuster V. Badimon JJ. Tissue factor modulatesthethrotnbogenicityof humanatherosclerotic plaqucs. 599. C-reactive protein:binding to lipids and lipoproteins. Int Rev Exp Pathol 1985;27:83- I I I . 76. Complement activation by C-reactive protein cotnplcxes. 5-250. 77. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactwe protein induces human peripheral blood monocytes t o synthesize tissue factor. 513-520. 78. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis.
N Engl J Med 1986: 3 14:4XX-S00. 1. Ross R. Thepathogenesis of atherosclerosis: a perspective f o r the 1 9 9 0 s . Nature l993:362:XOI -809. S . Ross R. Atherosc1erosis"anintlammatorydisease. N Engl J Med 199c);340: I IS-126. 6. Toss H, Lindahl B. Siegbnhn A, Wallentin L. Prognostic inllucnce of increased librinopen and C-reactive protein levcls i n unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation l997:96:4204-42 I O . 7. Liuzzo G.
Acute Coronary Syndromes, Third Edition by Eric Topol